Better Therapeutics BTTX · USD

Its shares trade under the ticker BTTX. It has been listed since 8 January 2021. In the fiscal year to 31 December 2020, it reported revenue of $8,000 and a net loss of $6.4m. At that date it held total assets of $6.4m and shareholders' equity of −$6.8m.

Better Therapeutics, Inc. operates as a digital therapeutics company, which engages in developing a novel form of cognitive behavioral therapy to address the root causes of cardio metabolic diseases. The company is headquartered in San Francisco, California. The company went IPO on 2021-01-08. The firm is engaged in developing a novel form of cognitive behavioral therapy (CBT) to address the root causes of cardiometabolic diseases. Its lead PDT product candidate, BT-001, is an investigational prescription digital therapy for the treatment of T2D. The investigational therapy is delivered via software that provides a tailored experience to patients designed to help them address the underlying causes of T2D by making meaningful, sustainable behavioral changes. The BT-001 investigational therapy is rooted in the well-studied, gold standard of behavioral modification therapies, cognitive behavioral therapy (CBT). The firm's platform consists of three behavioral therapy, treatment plans and personalization. Its behavioral therapy consists of lessons, skill- building modules, and a mechanism for goal setting. Its treatment plan is the primary engagement interface for patients.

Figures and description from our data supplier, not checked against the company's own report.

• Mr. Craig JalbertPresident, Chief Executive Officer, Treasurer, Company Secretary, Director, since 2024

Overall

0

Environment

0

Social

0

Governance

0

Data on this tab

Our data supplier

Chart on the Overview

TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.